There are many factors that affect the effectiveness of antiviral treatment of hepatitis B, the treatment is also an important reason for st
There are many factors that affect the effectiveness of antiviral treatment of hepatitis B, the treatment is also an important reason for standardization. Therefore:
First, the timing of treatment should be standardized
Not all people infected with the hepatitis B virus need immediate antiviral therapy. Chronic hepatitis B, serum transaminase activities recently (ALT) was higher than the normal limit of more than 2 times, is the best time for treatment of hepatitis B virus, these patients, if there is no special reason, it should be timely receiving antiretroviral treatment. For those times of liver function tests were normal patients, should according to different circumstances, the implementation of individualized treatment, patients in general, due to the effect of antiviral treatment is relatively poor, can temporarily without antiviral drugs and regular checkups, but if patients with previous hepatitis B attack history, there are still signs or symptoms or related liver disease there are other tests, imaging abnormalities, especially older than 40 years, there is a family history of hepatitis B and its related diseases, should make further examination, such as liver fibrosis, liver elasticity (hardness) determination, if necessary, should be such as liver biopsy, showed moderate or severe inflammation and / or histological manifestations of hepatic fibrosis. It should be listed as the object of antiviral therapy. As for patients with liver cirrhosis after hepatitis B, it should reduce the antiviral treatment threshold: as long as there is evidence of hepatitis B virus replication, whether or not elevated liver function transaminase, should be treated with antiviral therapy.
Two. Drug selection should be standardized
Recognized at home and abroad anti HBV drugs have two categories: one for the interferon, including general and pegylated interferon (commonly known as "interferon"), the other is the nucleoside (acid) analogues, the existing domestic A Duff Vee, lamivudine, entecavir and telbivudine, these two types of six kinds of drugs in antiviral intensity inhibition of virus replication, speed, safety, resistance rate and price etc. the length of each, according to the condition of the patients, infection time, no complications, age and even gender and treatment ability (including economic conditions) and other factors into consideration, reasonable selection. For example, patients were younger, better treatment compliance, low viral load, the interferon treatment, can often achieve better effect, on the contrary, in patients with liver cirrhosis is not or cannot use interferon, nucleoside analogues should choose strong and long-term application of incidence of drug resistance is low, or two kinds of nucleoside analogues combined with.